Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, Richard W Joseph, J. S. Weber, Roxana S Dronca, T. C. Mitchell, A. Patnaik, H. M. Zarour, A. M. Joshua, Q. Zhao, E. Jensen, S. Ahsan, N. Ibrahim, A. Ribas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS: Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. CONCLUSIONS: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov, NCT01295827.

Original languageEnglish (US)
Pages (from-to)582-588
Number of pages7
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume30
Issue number4
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Melanoma
Survival
Disease-Free Survival
pembrolizumab
Therapeutics
Research Personnel
Kaplan-Meier Estimate
Disease Progression
Survival Rate
Observation
Safety

Keywords

  • long-term follow-up
  • melanoma
  • metastatic
  • overall survival
  • pembrolizumab
  • treatment-naive

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. / Hamid, O.; Robert, C.; Daud, A.; Hodi, F. S.; Hwu, W. J.; Kefford, R.; Wolchok, J. D.; Hersey, P.; Joseph, Richard W; Weber, J. S.; Dronca, Roxana S; Mitchell, T. C.; Patnaik, A.; Zarour, H. M.; Joshua, A. M.; Zhao, Q.; Jensen, E.; Ahsan, S.; Ibrahim, N.; Ribas, A.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, No. 4, 01.04.2019, p. 582-588.

Research output: Contribution to journalArticle

Hamid, O, Robert, C, Daud, A, Hodi, FS, Hwu, WJ, Kefford, R, Wolchok, JD, Hersey, P, Joseph, RW, Weber, JS, Dronca, RS, Mitchell, TC, Patnaik, A, Zarour, HM, Joshua, AM, Zhao, Q, Jensen, E, Ahsan, S, Ibrahim, N & Ribas, A 2019, 'Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, no. 4, pp. 582-588. https://doi.org/10.1093/annonc/mdz011
Hamid, O. ; Robert, C. ; Daud, A. ; Hodi, F. S. ; Hwu, W. J. ; Kefford, R. ; Wolchok, J. D. ; Hersey, P. ; Joseph, Richard W ; Weber, J. S. ; Dronca, Roxana S ; Mitchell, T. C. ; Patnaik, A. ; Zarour, H. M. ; Joshua, A. M. ; Zhao, Q. ; Jensen, E. ; Ahsan, S. ; Ibrahim, N. ; Ribas, A. / Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2019 ; Vol. 30, No. 4. pp. 582-588.
@article{5bd650ac115c49a985d8c99af35f2390,
title = "Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001",
abstract = "BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS: Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34{\%} in all patients and 41{\%} in treatment-naive patients; median OS was 23.8 months (95{\%} CI, 20.2-30.4) and 38.6 months (95{\%} CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21{\%} in all patients and 29{\%} in treatment-naive patients; median PFS was 8.3 months (95{\%} CI, 5.8-11.1) and 16.9 months (95{\%} CI, 9.3-35.5), respectively. Median response duration was not reached; 73{\%} of all responses and 82{\%} of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86{\%} of patients and resulted in study discontinuation in 7.8{\%}; 17{\%} experienced grade 3/4 TRAE. CONCLUSIONS: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov, NCT01295827.",
keywords = "long-term follow-up, melanoma, metastatic, overall survival, pembrolizumab, treatment-naive",
author = "O. Hamid and C. Robert and A. Daud and Hodi, {F. S.} and Hwu, {W. J.} and R. Kefford and Wolchok, {J. D.} and P. Hersey and Joseph, {Richard W} and Weber, {J. S.} and Dronca, {Roxana S} and Mitchell, {T. C.} and A. Patnaik and Zarour, {H. M.} and Joshua, {A. M.} and Q. Zhao and E. Jensen and S. Ahsan and N. Ibrahim and A. Ribas",
year = "2019",
month = "4",
day = "1",
doi = "10.1093/annonc/mdz011",
language = "English (US)",
volume = "30",
pages = "582--588",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

AU - Hamid, O.

AU - Robert, C.

AU - Daud, A.

AU - Hodi, F. S.

AU - Hwu, W. J.

AU - Kefford, R.

AU - Wolchok, J. D.

AU - Hersey, P.

AU - Joseph, Richard W

AU - Weber, J. S.

AU - Dronca, Roxana S

AU - Mitchell, T. C.

AU - Patnaik, A.

AU - Zarour, H. M.

AU - Joshua, A. M.

AU - Zhao, Q.

AU - Jensen, E.

AU - Ahsan, S.

AU - Ibrahim, N.

AU - Ribas, A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS: Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. CONCLUSIONS: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov, NCT01295827.

AB - BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS: Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. CONCLUSIONS: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov, NCT01295827.

KW - long-term follow-up

KW - melanoma

KW - metastatic

KW - overall survival

KW - pembrolizumab

KW - treatment-naive

UR - http://www.scopus.com/inward/record.url?scp=85065574127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065574127&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz011

DO - 10.1093/annonc/mdz011

M3 - Article

VL - 30

SP - 582

EP - 588

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -